27
Participants
Start Date
December 31, 2013
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Regorafenib (Stivarga, BAY73-4506)
single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
Neomycin
1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
Berlin
Lead Sponsor
Bayer
INDUSTRY